Product Review: Tecentriq® (atezolizumab) in unresectable hepatocellular carcinoma

In this review:

Tecentriq® (atezolizumab) is a humanised, engineered, IgG1 monoclonal antibody targeting programmed death ligand-1 (PD-L1). In New Zealand, atezolizumab in combination with Avastin® (bevacizumab), is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The aim of this review is to describe important safety and efficacy data for atezolizumab in patients with HCC. This publication has been commissioned by Roche Products (New Zealand) Limited.

Please login below to download this issue (PDF)